Key facts
- This page summarizes Chaim Lebovits's Form 4 filing for BRAINSTORM CELL THERAPEUTICS INC. (BCLI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 03 Jan 2025, 17:36.
Chaim Lebovits - 01 Jan 2025 Form 4 Insider Report for BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
- Reporting relationship
- President & CEO
- Issuer ticker
- BCLI
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 17:36:42 UTC
- Prior SEC filing
- 02 Oct 2024
- Next SEC filing
- 29 May 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chaim Lebovits
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Chaim Lebovits filed Form 4 for BRAINSTORM CELL THERAPEUTICS INC. (BCLI) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 02 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BCLI
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +120,000
- Change %
- +148%
- Price
- $0.000000
- Shares after
- 200,960
- Date
- 01 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
BCLI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 133,389
- Date
- 01 Jan 2025
- Ownership
- See footnote
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Footnote F2
Includes (i) 128,919 shares of Common Stock owned by ACCBT Corp. and (ii) 4,470 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may be deemed the beneficial owner of these shares.